echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Bayer company announced that it will carry out phase III clinical trial of new arbacicept 8 mg preparation

    Bayer company announced that it will carry out phase III clinical trial of new arbacicept 8 mg preparation

    • Last Update: 2020-02-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bayer and regeneron pharmaceuticals, Inc today announced that they will carry out two phase III studies, photon and pulsar, to assess the prolongation of the interval between the treatment of intravitreal injection of a new 8 mg formulation of abacept in adult patients with visual impairment caused by diabetic macular edema (DME) and neovascular age-related macular degeneration (wet AMD), respectively Abacetep intraocular injection solution (2mg) trade name is aliya, in more than 100 countries, five indications have been approved for marketing Two trials are scheduled to begin in 2020 The basic principles of the two experiments were put forward at the American annual conference on neovascularization in 2020 A multicenter, randomized, double-blind trial will evaluate the efficacy and safety of arbacicept 8mg in 12 weeks (3 months) or more Dr Joerg Moeller, executive committee member and R & D director of Bayer's prescription medicine business department, said: "we have seen that some patients can achieve good visual effects by using abacept 2mg when the interval of administration is extended to 16 weeks (4 months), especially in Europe and several other regions with approved treatment and extension programs The photon and pulsar trials will assess whether more patients benefit from the longer treatment interval regimen of 8 mg arbacip " Bayer and regeneron pharmaceuticals, Inc are collaborating on the global development business of AB cept Regeneron holds the exclusive rights of aliya in the United States and Bayer has the exclusive marketing license outside the United States Outside Japan, Bayer and regeneron pharmaceuticals, Inc share the sales profit of aliya equally; in Japan, regeneron obtains a certain proportion of net sales Vascular endothelial growth factor (VEGF) is a kind of natural cell factor in human body It can promote the formation of new blood vessels in normal human body, so as to support the growth of tissues and organs in the body It is also related to the formation of abnormal neovascularization in the eye, which increases the permeability of blood vessels and leads to retinal edema Arbacicept for injection is a recombinant fusion protein formed by fusion of human vascular endothelial growth factor receptor 1 and two extracellular domains with Fc domain of human IgG1, which is prepared into isotonic solution for injection in vivo As a soluble decoy receptor, arbacip binds to VEGF-A, VEGF-B and PGF, and inhibits the binding and activation of these factors to natural VEGF receptor Aliyah is the trade name of abacept's intraocular injection solution Five adult indications have been approved for marketing in more than 100 countries around the world It is mainly used for the treatment of neovascular age-related macular degeneration (wet AMD) and other retinopathy causing visual impairment, including retinal vein occlusion (RVO, including BRVO and CRVO), diabetic macular edema (DME) and visual impairment caused by pathological myopic choroidal neovascularization (myopic CNV) are also approved Since the launch of abacept's intraocular injection solution, the global use has exceeded 30 million, and it is estimated that it has more than 4 million patient years of experience.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.